MedTrace Logo

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

NCT04102982 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-11-02

No results posted yet for this study

Summary

Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.

Conditions

  • NSCLC Stage IV

Interventions

DRUG

Camrelizumab

Patients will be treated with camrelizumab alone.

OTHER

Camrelizumab plus microwave ablation

In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.

Sponsors & Collaborators

  • Shandong Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Xin Ye · Shandong Provincial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2021-10-31
Completion
2022-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04102982 on ClinicalTrials.gov